Implication of CD154/CD40 interaction in healthy and autoimmune responses

Current Immunology Reviews

Volumn 5, Issue 4, 2009, Pages 285-299

  Hassan, Ghada S ^a   Rana, Manjit ^a   Léveillé, Claire ^a   Nadiri, Amal ^a   Jundi, Malek ^a   Polyak, Maria ^a   El Fakhry, Youssef ^a   Mourad, Walid M ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

CD154; CD40; Immune cells; Inflammatory autoimmune diseases; Integrins

Indexed keywords

ALPHA2BBETA3 INTEGRIN; ALPHAVBETA1 INTEGRIN; BG 9588; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; INTEGRIN; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY IDEC 1; MONOCLONAL ANTIBODY IDEC 131; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

EID: 70350782347     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339509789503989     Document Type: Review

References (121)

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501. (Pubitemid 32201945)
2. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
3. Kaufman J, Sime PJ, Phipps RP. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-gamma and IL-13, and implications for fibrosis. J Immunol 2004; 172:1862-1871.
4. Santilli F, Basili S, Ferroni P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007; 2: 256-268
5. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000; 50:184-195 (Pubitemid 30610095)
6. Fanslow WC, Srinivasan S, Paxton R, Gibson MG, Spriggs MK, Armitage RJ. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 1994; 6: 267-278 (Pubitemid 124001524)
7. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995; 25:1749-1754
8. Fischer KP, Gares SL, Wang D, Lorne Tyrrell D, Gutfreund KS. Identification and characterization of functional CD154 (CD40 ligand) in the Pekin duck. Dev Comp Immunol 2007; 31: 61-71. (Pubitemid 44467971)
9. Pietravalle F, Lecoanet HS, Blasey H, et al. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996; 271: 5965-5967 (Pubitemid 26095393)
10. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82. (Pubitemid 32281113)
11. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 8: 247-252 (Pubitemid 34250102)
12. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896-899 (Pubitemid 34925319)
13. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98:1047-1054
14. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992; 89: 6550-6554
15. Leveille C, Bouillon M, Guo W, et al. CD40 Ligand Binds to {alpha}5beta1 Integrin and Triggers Cell Signaling. J Biol Chem 2007; 282: 5143-5151 (Pubitemid 47093769)
16. Zirlik A, Maier C, Gerdes N, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007; 115:1571-1580 (Pubitemid 46648642)
17. Singh J, Garber E, Van Vlijmen H, et al. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci 1998; 7: 1124-1135 (Pubitemid 28237044)
18. Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci 1998; 23: 74-79
19. Reyes-Moreno C, Sharif-Askari E, Girouard J, et al. Requirement of oxidation-dependent CD40 homodimers for CD154/CD40 bidirectional signaling. J Biol Chem 2007; 282:19473-19480 (Pubitemid 47100115)
20. Bock J, Gulbins E. The transmembranous domain of CD40 determines CD40 partitioning into lipid rafts. FEBS Lett 2003; 534: 169-174 (Pubitemid 36084537)
21. Danese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 2005; 25: 103-121 (Pubitemid 40910584)
22. Tan J, Town T, Mori T, et al. CD40 is expressed and functional on neuronal cells. EMBO J 2002; 21: 643-652 (Pubitemid 34174045)
23. Klein D, Barbe-Tuana F, Pugliese A, et al. A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia 2005; 48: 268-276 (Pubitemid 40543298)
24. Klein D, Timoneri F, Ichii H, Ricordi C, Pastori RL. CD40 activation in human pancreatic islets and ductal cells. Diabetologia 2008; 51(10): 1853-1861
25. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
26. Mukundan L, Milhorn DM, Matta B, Suttles J. CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway. Cell Signal 2004; 16: 375-384 (Pubitemid 37542412)
27. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687
28. Bennett JS. Platelet-fibrinogen interactions. Ann NY Acad Sci 2001; 936: 340-354
29. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003; 100:12367-12371 (Pubitemid 37271566)
30. Foy T, Aruffo A, Bajorath J, Buhlmann J, Noelle R. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996; 14: 591-617. (Pubitemid 26130658)
31. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 2004; 53: 1035-1043 (Pubitemid 38824165)
32. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995; 378: 617-620
33. Lee BO, Haynes L, Eaton SM, Swain SL, Randall TD. The biological outcome of CD40 signaling is dependent on the duration of CD40 ligand expression: reciprocal regulation by interleukin (IL)-4 and IL-12. J Exp Med 2002; 196: 693-704. (Pubitemid 35024446)
34. Reyes-Moreno C, Girouard J, Lapointe R, Darveau A, Mourad W. CD40/CD40 homodimers are required for CD40-induced phosphatidylinositol 3-kinase-dependent expression of B7.2 by human B lymphocytes. J Biol Chem 2004; 279: 7799-7806 (Pubitemid 38294664)
35. Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J Immunol 1996; 156: 2345-2348 (Pubitemid 26091553)
36. Dadgostar H, Zarnegar B, Hoffmann A, et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA 2002; 99:1497-1502 (Pubitemid 34136521)
37. Hanissian S, Geha R. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997; 6: 379-387 (Pubitemid 27208193)
38. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13:1083-1088 (Pubitemid 46424046)
39. Ren CL, Morio T, Fu SM, Geha RS. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med 1994; 179: 673-680
40. Davies CC, Mak TW, Young LS, Eliopoulos AG. TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol Cell Biol 2005; 25: 9806-9819
41. Pullen SS, Dang TT, Crute JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 1999; 274: 14246-14254 (Pubitemid 129518736)
42. Grammer AC, Lipsky PE. CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv Immunol 2000; 76: 61-178.
43. Bishop GA, Hostager BS, Brown KD. Mechanisms of TNF receptor-associated factor (TRAF) regulation in B lymphocytes. J Leukoc Biol 2002; 72: 19-23.
44. Vallabhapurapu S, Matsuzawa A, Zhang W, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008; 9:1364-1370
45. Fotin-Mleczek M, Henkler F, Hausser A, et al. Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation. J Biol Chem 2004; 279: 677-685 (Pubitemid 38044872)
46. Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA. Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. J Immunol 2006; 176: 5388-5400
47. Grammer AC, Swantek JL, McFarland RD, Miura Y, Geppert T, Lipsky PE. TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. J Immunol 1998; 161: 1183-1193 (Pubitemid 28380544)
48. Jabara H, Laouini D, Tsitsikov E, et al. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching. Immunity 2002; 17: 265-276 (Pubitemid 35279548)
49. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 2006; 13:1789-1801 (Pubitemid 44390865)
50. Yellin MJ, Sinning J, Covey LR, et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994; 153: 666-674 (Pubitemid 24206295)
51. Liu YJ, Barthelemy C, de Bouteiller O, Arpin C, Durand I, Banchereau J. Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2. Immunity 1995; 2: 239-248
52. Ballantyne J, Henry DL, Muller JR, et al. Efficient recombination of a switch substrate retrovector in CD40-activated B lymphocytes: implications for the control of CH gene switch recombination. J Immunol 1998; 161: 1336-1347 (Pubitemid 28380562)
53. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881-922.
54. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180:1263-1272 (Pubitemid 24289600)
55. Peguet NJ, Dalbiez GC, Rattis FM, Van KC, Banchereau J, Schmitt D. Functional expression of CD40 antigen on human epidermal Langerhans cells. J Immunol 1995; 155: 4241-4247
56. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752 (Pubitemid 26324129)
57. Koch F, Stanzl U, Jennewein P, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996; 184: 741-746
58. Iezzi G, Sonderegger I, Ampenberger F, Schmitz N, Marsland BJ, Kopf M. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci USA 2009; 106: 876-881
59. Suttles J, Evans M, Miller R, Poe J, Stout R, Wahl L. T cell rescue of monocytes from apoptosis: role of the CD40-CD40L interaction and requirement for CD40-mediated induction of protein tyrosine kinase activity. J Leukoc Biol 1996; 60: 651-657 (Pubitemid 26400423)
60. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-780. (Pubitemid 28292195)
61. Roth E, Schwartzkopff J, Pircher H. CD40 Ligation in the Presence of Self-Reactive CD8 T Cells Leads to Severe Immunopathology. J Immunol 2002; 168: 5124-5129 (Pubitemid 34495977)
62. Ridge JP, Di RF, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478 (Pubitemid 28292194)
63. MacDonald KPA, Nishioka Y, Lipsky PE, Thomas R. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J. Clin. Invest 1997; 100: 2404-2414 (Pubitemid 27500166)
64. Gerritse K, Laman J, Noelle R, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996; 93: 2499-2504 (Pubitemid 26104798)
65. Faure G, Bensoussan-Lejzerowicz D, Bene M, Aubert V, Leclere J. Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells. J Clin Immunol Immunopathol 1997; 84: 212-215 (Pubitemid 27353475)
66. Sugiura T, Kawaguchi Y, Harigai M, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 2000; 164: 6593-6600 (Pubitemid 30408846)
67. Yamauchi PS, Bleharski JR, Uyemura K, et al. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. J Immunol 2000; 165:1506-1512 (Pubitemid 30604585)
68. Liu Z, Colpaert S, D'Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 1999; 163: 4049-4057 (Pubitemid 29450936)
69. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220-228
70. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915 (Pubitemid 37409707)
71. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 1328-1330 (Pubitemid 24081170)
72. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 1999; 90: 65-78. (Pubitemid 29162185)
73. Berner B, Wolf G, Hummel KM, Muller GA, Reuss-Borst MA. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 190-195 (Pubitemid 30305588)
74. Wagner UG, Kurtin PJ, Wahner A, et al. The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol 1998; 161: 6390-6397 (Pubitemid 28536016)
75. Liu MF, Chao SC, Wang CR, Lei HY. Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 2001; 34: 107-113
76. Tighe H, Heaphy P, Baird S, Weigle WO, Carson DA. Human immunoglobulin (IgG) induced deletion of IgM rheumatoid factor B cells in transgenic mice. J Exp Med 1995; 181: 599-606.
77. Kyburz D, Corr M, Brinson DC, Von Damm A, Tighe H, Carson DA. Human rheumatoid factor production is dependent on CD40 signaling and autoantigen. J Immunol 1999; 163: 3116-3122 (Pubitemid 29431809)
78. Sekine C, Yagita H, Miyasaka N, Okumura K. Expression and function of CD40 in rheumatoid arthritis synovium. J Rheumatol 1998; 25: 1048-1053 (Pubitemid 28350873)
79. Kiener PA, Moran Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995; 155: 4917-4925
80. Wagner DH, Jr., Stout RD, Suttles J. Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol 1994; 24: 3148-3154
81. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38. (Pubitemid 351182593)
82. Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007; 17:118-123
83. Yellin MJ, Winikoff S, Fortune SM, et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) upregulation and IL-6 production and proliferation. J Leukoc Biol 1995; 58: 209-216
84. Gotoh H, Kawaguchi Y, Harigai M, et al. Increased CD40 expression on articular chondrocytes from patients with rheumatoid arthritis: contribution to production of cytokines and matrix metalloproteinases. J Rheumatol 2004; 31:1506-1512 (Pubitemid 39006630)
85. Kyburz D, Carson DA, Corr M. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2571-2577 (Pubitemid 30829283)
86. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301: 1374-1377 (Pubitemid 37075812)
87. Desai MA, Lu L, Ramsey GR, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-2073 (Pubitemid 26143961)
88. Devi BS, Van Noordin S, Krausz T, Davies KA. Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun 1998; 11: 471-475 (Pubitemid 28520203)
89. Higuchi T, Aiba Y, Nomura T, et al. Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol 2002; 168: 9-12. (Pubitemid 34014096)
90. Blossom S, Chu E, Weigle W, Gilbert K. CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus. J Immunol 1997; 159: 4580-4586 (Pubitemid 127470620)
91. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002; 46:1417-1429
92. Koshy M, Berger D, Crow M. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-837 (Pubitemid 26349188)
93. Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 2002; 103: 54-62.
94. Kato K, Santana-Sahagun E, Rassenti LZ, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 947-955 (Pubitemid 29536344)
95. Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000; 165: 6627-6634
96. Kalled SL, Cutler AH, Ferrant JL. Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis. Lupus 2001; 10: 9-22.
97. Early G, Zhao W, Burns C. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996; 157: 3159-3164 (Pubitemid 126450078)
98. Wang X, Huang W, Mihara M, Sinha J, Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002; 168: 2046-2053 (Pubitemid 34135809)
99. Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005; 252(Suppl 5): v3-9. (Pubitemid 41532349)
100. Filion LG, Matusevicius D, Graziani-Bowering GM, Kumar A, Freedman MS. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin Immunol 2003; 106:127-138
101. Laman JD, De Boer M, Hart BA. CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Dev Immunol 1998; 6: 215-222 (Pubitemid 28517778)
102. Gerritse K, Deen C, Fasbender M, Ravid R, Boersma W, Claassen E. The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology. J Neuroimmunol 1994; 49:153-159 (Pubitemid 24071764)
103. Schaub M, Issazadeh S, Stadlbauer TH, Peach R, Sayegh MH, Khoury SJ. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 1999; 96:158-166 (Pubitemid 29234490)
104. Grewal IS, Foellmer HG, Grewal KD, et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273:1864-1867
105. Molano RD, Berney T, Li H, et al. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. Diabetes 2001; 50: 270-276 (Pubitemid 32127282)
106. Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004; 103: 1229-1236 (Pubitemid 38168632)
107. Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 2008; 141: 545-548 (Pubitemid 351550547)
108. Balasa B, Krahl T, Patstone G, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159: 4620-4627 (Pubitemid 127470625)
109. Li XL, Menoret S, Le Mauff B, Angin M, Anegon I. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation 2008; 86:10-15
110. Masunaga T, Yamashita K, Sakihama H, et al. Dimeric but not monomeric soluble CD40 prolongs allograft survival and generates regulatory T cells that inhibit CTL function. Transplantation 2005; 80:1614-1622 (Pubitemid 43005873)
111. Meng L, Wu Z, Wang Y, et al. Differential impact of CD154 costimulation blockade on alloreactive effector and regulatory T cells in murine renal transplant recipients. Transplantation 2008; 85:1332-1338 (Pubitemid 351670485)
112. Kalunian KC, Davis JC, Jr., Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 3251-3258 (Pubitemid 35453534)
113. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727 (Pubitemid 36302008)
114. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004; 37: 457-464 (Pubitemid 40123415)
115. Gao D, Wagner AH, Fankhaenel S, et al. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut 2005; 54:70-77 (Pubitemid 40007220)
116. Allen SD, Rawale SV, Whitacre CC, Kaumaya PT. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res 2005; 65: 591-604.
117. Pluvinet R, Petriz J, Torras J, et al. RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 2004; 104: 3642-3646 (Pubitemid 39564440)
118. Zheng X, Vladau C, Zhang X, et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009; 113(12): 2646-2654
119. Suzuki M, Zheng X, Zhang X, et al. Inhibition of allergic responses by CD40 gene silencing. Allergy 2009; 64(3): 389-397
120. Bajorath J, Chalupny NJ, Marken JS, et al. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. Biochemistry 1995; 34: 1833-1844
121. Bajorath J, Marken JS, Chalupny NJ, et al. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry 1995; 34: 9884-9892